nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—DRD3—attention deficit hyperactivity disorder	0.477	0.591	CbGaD
Metoclopramide—DRD2—attention deficit hyperactivity disorder	0.33	0.409	CbGaD
Metoclopramide—CYP11B2—cardiovascular system—attention deficit hyperactivity disorder	0.00269	0.113	CbGeAlD
Metoclopramide—HTR4—brain—attention deficit hyperactivity disorder	0.00235	0.0981	CbGeAlD
Metoclopramide—Bromopride—DRD2—attention deficit hyperactivity disorder	0.00172	0.237	CrCbGaD
Metoclopramide—HTR3A—forebrain—attention deficit hyperactivity disorder	0.00153	0.0638	CbGeAlD
Metoclopramide—Amisulpride—DRD3—attention deficit hyperactivity disorder	0.0013	0.18	CrCbGaD
Metoclopramide—DRD3—nervous system—attention deficit hyperactivity disorder	0.0012	0.0501	CbGeAlD
Metoclopramide—CHRM1—forebrain—attention deficit hyperactivity disorder	0.00116	0.0485	CbGeAlD
Metoclopramide—DRD3—central nervous system—attention deficit hyperactivity disorder	0.00115	0.0482	CbGeAlD
Metoclopramide—CYP17A1—nervous system—attention deficit hyperactivity disorder	0.00106	0.0442	CbGeAlD
Metoclopramide—CYP17A1—central nervous system—attention deficit hyperactivity disorder	0.00102	0.0425	CbGeAlD
Metoclopramide—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.000981	0.041	CbGeAlD
Metoclopramide—DRD2—forebrain—attention deficit hyperactivity disorder	0.000934	0.039	CbGeAlD
Metoclopramide—DRD3—brain—attention deficit hyperactivity disorder	0.000916	0.0383	CbGeAlD
Metoclopramide—Amisulpride—DRD2—attention deficit hyperactivity disorder	0.000901	0.124	CrCbGaD
Metoclopramide—Chloroprocaine—SLC6A3—attention deficit hyperactivity disorder	0.000854	0.118	CrCbGaD
Metoclopramide—HTR3A—nervous system—attention deficit hyperactivity disorder	0.000829	0.0346	CbGeAlD
Metoclopramide—Procaine—SLC6A3—attention deficit hyperactivity disorder	0.000814	0.112	CrCbGaD
Metoclopramide—CYP17A1—brain—attention deficit hyperactivity disorder	0.000807	0.0338	CbGeAlD
Metoclopramide—HTR3A—central nervous system—attention deficit hyperactivity disorder	0.000798	0.0334	CbGeAlD
Metoclopramide—Amisulpride—HTR2A—attention deficit hyperactivity disorder	0.000696	0.0962	CrCbGaD
Metoclopramide—HTR3A—brain—attention deficit hyperactivity disorder	0.000634	0.0265	CbGeAlD
Metoclopramide—CHRM1—nervous system—attention deficit hyperactivity disorder	0.00063	0.0263	CbGeAlD
Metoclopramide—DRD2—midbrain—attention deficit hyperactivity disorder	0.000617	0.0258	CbGeAlD
Metoclopramide—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.000606	0.0253	CbGeAlD
Metoclopramide—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000561	0.0235	CbGeAlD
Metoclopramide—Cisapride—DRD2—attention deficit hyperactivity disorder	0.00054	0.0745	CrCbGaD
Metoclopramide—DRD2—nervous system—attention deficit hyperactivity disorder	0.000507	0.0212	CbGeAlD
Metoclopramide—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000488	0.0204	CbGeAlD
Metoclopramide—CHRM1—brain—attention deficit hyperactivity disorder	0.000481	0.0201	CbGeAlD
Metoclopramide—DRD2—cerebellum—attention deficit hyperactivity disorder	0.000477	0.0199	CbGeAlD
Metoclopramide—Cisapride—HTR2A—attention deficit hyperactivity disorder	0.000417	0.0576	CrCbGaD
Metoclopramide—DRD2—brain—attention deficit hyperactivity disorder	0.000388	0.0162	CbGeAlD
Metoclopramide—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000305	0.0127	CbGeAlD
Metoclopramide—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000293	0.0123	CbGeAlD
Metoclopramide—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000287	0.012	CbGeAlD
Metoclopramide—CYP2D6—brain—attention deficit hyperactivity disorder	0.000233	0.00973	CbGeAlD
Metoclopramide—HTR4—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000127	0.000788	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000127	0.000787	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000126	0.000785	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.000126	0.000781	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.000126	0.000781	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000124	0.00077	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000124	0.00077	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000123	0.000766	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.000123	0.000764	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.000123	0.000764	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.000122	0.000756	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000122	0.000756	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000122	0.000756	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000121	0.000754	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000119	0.000742	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000119	0.000741	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000119	0.00074	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.000119	0.00074	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000119	0.00074	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000119	0.000739	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.000118	0.000734	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000118	0.000733	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000118	0.000732	CbGpPWpGaD
Metoclopramide—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000118	0.000731	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000117	0.000729	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000117	0.000725	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000116	0.00072	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.000116	0.000718	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000115	0.000716	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000111	0.000688	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00011	0.000681	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000109	0.000674	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000108	0.000673	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000108	0.000673	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000108	0.000671	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000108	0.000671	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.000108	0.000669	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000107	0.000667	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000106	0.00066	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000106	0.000656	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000104	0.000648	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000103	0.000639	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000103	0.000637	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000102	0.000632	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000101	0.000627	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000101	0.000626	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.0001	0.000623	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	9.97e-05	0.000619	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	9.8e-05	0.000609	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	9.76e-05	0.000606	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	9.68e-05	0.000601	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	9.59e-05	0.000596	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.52e-05	0.000591	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	9.49e-05	0.000589	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	9.47e-05	0.000588	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.44e-05	0.000586	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	9.31e-05	0.000578	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	9.28e-05	0.000577	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	9.11e-05	0.000566	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	8.99e-05	0.000558	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.97e-05	0.000557	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	8.82e-05	0.000548	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	8.82e-05	0.000548	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.81e-05	0.000547	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.78e-05	0.000545	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	8.63e-05	0.000536	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	8.54e-05	0.00053	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	8.4e-05	0.000521	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	8.36e-05	0.000519	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.36e-05	0.000519	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.33e-05	0.000517	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	8.29e-05	0.000515	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	8.27e-05	0.000513	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	8.25e-05	0.000512	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.25e-05	0.000512	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	8.22e-05	0.00051	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	8.16e-05	0.000507	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TPH2—attention deficit hyperactivity disorder	8.15e-05	0.000506	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.15e-05	0.000506	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	8.12e-05	0.000504	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	8.09e-05	0.000502	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—DPYD—attention deficit hyperactivity disorder	8.02e-05	0.000498	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8e-05	0.000497	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	8e-05	0.000496	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.84e-05	0.000487	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.69e-05	0.000477	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.57e-05	0.00047	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	7.56e-05	0.000469	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.45e-05	0.000463	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.29e-05	0.000452	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	7.22e-05	0.000449	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.19e-05	0.000446	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	7.15e-05	0.000444	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.07e-05	0.000439	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	7.07e-05	0.000439	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.06e-05	0.000438	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TPH2—attention deficit hyperactivity disorder	7.02e-05	0.000436	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.02e-05	0.000436	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.94e-05	0.000431	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—DPYD—attention deficit hyperactivity disorder	6.91e-05	0.000429	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	6.88e-05	0.000427	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.85e-05	0.000425	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	6.74e-05	0.000418	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	6.73e-05	0.000418	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	6.72e-05	0.000417	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	6.6e-05	0.00041	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	6.57e-05	0.000408	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TPH2—attention deficit hyperactivity disorder	6.57e-05	0.000408	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.57e-05	0.000408	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.52e-05	0.000405	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.5e-05	0.000404	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—DPYD—attention deficit hyperactivity disorder	6.46e-05	0.000401	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.42e-05	0.000399	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	6.39e-05	0.000397	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.38e-05	0.000396	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.37e-05	0.000395	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.32e-05	0.000392	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.31e-05	0.000392	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.29e-05	0.000391	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	6.26e-05	0.000389	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.25e-05	0.000388	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.25e-05	0.000388	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.21e-05	0.000385	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.2e-05	0.000385	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.18e-05	0.000384	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.18e-05	0.000384	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.12e-05	0.00038	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.11e-05	0.00038	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.1e-05	0.000379	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.01e-05	0.000373	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.99e-05	0.000372	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.76e-05	0.000357	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.62e-05	0.000349	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.61e-05	0.000348	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.54e-05	0.000344	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.5e-05	0.000342	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.41e-05	0.000336	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.38e-05	0.000334	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.38e-05	0.000334	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.35e-05	0.000332	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	5.34e-05	0.000332	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.34e-05	0.000331	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.3e-05	0.000329	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.25e-05	0.000326	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5e-05	0.00031	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.96e-05	0.000308	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—COMT—attention deficit hyperactivity disorder	4.94e-05	0.000307	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—MAOA—attention deficit hyperactivity disorder	4.9e-05	0.000304	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.85e-05	0.000301	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.82e-05	0.000299	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.76e-05	0.000295	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.72e-05	0.000293	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.72e-05	0.000293	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.67e-05	0.00029	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.66e-05	0.00029	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.63e-05	0.000288	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.57e-05	0.000284	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.5e-05	0.00028	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.47e-05	0.000278	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.34e-05	0.00027	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.29e-05	0.000267	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.29e-05	0.000266	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—COMT—attention deficit hyperactivity disorder	4.26e-05	0.000264	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.24e-05	0.000263	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.24e-05	0.000263	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—MAOA—attention deficit hyperactivity disorder	4.23e-05	0.000262	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.2e-05	0.000261	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.15e-05	0.000258	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.12e-05	0.000256	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.1e-05	0.000254	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	4.09e-05	0.000254	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.08e-05	0.000254	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.03e-05	0.00025	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	4e-05	0.000248	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4e-05	0.000248	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—COMT—attention deficit hyperactivity disorder	3.98e-05	0.000247	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—MAOA—attention deficit hyperactivity disorder	3.95e-05	0.000245	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.95e-05	0.000245	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.83e-05	0.000238	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.8e-05	0.000236	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.71e-05	0.000231	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.71e-05	0.00023	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.69e-05	0.000229	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.68e-05	0.000228	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.63e-05	0.000225	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.61e-05	0.000224	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.61e-05	0.000224	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.61e-05	0.000224	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.6e-05	0.000223	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.57e-05	0.000222	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.55e-05	0.00022	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.54e-05	0.00022	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.54e-05	0.00022	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.49e-05	0.000217	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.47e-05	0.000215	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.45e-05	0.000214	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.37e-05	0.000209	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.34e-05	0.000207	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.28e-05	0.000204	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.27e-05	0.000203	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.27e-05	0.000203	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.25e-05	0.000202	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.24e-05	0.000201	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.21e-05	0.000199	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.17e-05	0.000197	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.04e-05	0.000189	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.95e-05	0.000183	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.86e-05	0.000178	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.76e-05	0.000172	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.66e-05	0.000165	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.57e-05	0.00016	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.53e-05	0.000157	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.51e-05	0.000156	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.5e-05	0.000155	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.45e-05	0.000152	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.37e-05	0.000147	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.33e-05	0.000145	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.33e-05	0.000145	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.28e-05	0.000141	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.19e-05	0.000136	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.14e-05	0.000133	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—EP300—attention deficit hyperactivity disorder	2.12e-05	0.000131	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.11e-05	0.000131	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.07e-05	0.000128	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.04e-05	0.000126	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.99e-05	0.000124	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.97e-05	0.000122	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.94e-05	0.00012	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.93e-05	0.00012	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.91e-05	0.000119	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.9e-05	0.000118	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.87e-05	0.000116	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—EP300—attention deficit hyperactivity disorder	1.83e-05	0.000113	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.78e-05	0.00011	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.78e-05	0.00011	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.75e-05	0.000109	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.75e-05	0.000108	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—EP300—attention deficit hyperactivity disorder	1.71e-05	0.000106	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.63e-05	0.000101	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.63e-05	0.000101	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.42e-05	8.82e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.35e-05	8.4e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.25e-05	7.76e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.22e-05	7.59e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.08e-05	6.68e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.07e-05	6.64e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.65e-06	5.37e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.62e-06	4.11e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.48e-06	4.02e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	4.62e-06	2.87e-05	CbGpPWpGaD
